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  2 
We agree with Timire and colleagues that all financial barriers faced by people with TB at all stages of 1 
the care cascade should be addressed if we are to achieve the ambitious targets set by the End TB 2 
Strategy and the Sustainable Development Goals. Further evidence on economic hardship during 3 
pathways to care, and also after treatment completion, is warranted. Several studies are ongoing, 4 
including “TBSequel”, which tracks costs after completed TB treatment in four African countries (1).  5 
 6 
Although national TB patient cost surveys focus on diagnosed TB patients, they also aim to capture 7 
retrospective information about pre-diagnosis costs related to seeking care (2). In addition, the survey 8 
instrument can be incorporated into patient pathway analyses, prospective studies and trials and 9 
thereby provide important complementary information.  10 
 11 
The design and sampling strategy are as important as the choice of the instrument. Even studies with 12 
inception during the diagnostic pathway will inevitably miss those that never seek or receive any care, 13 
or do so at facilities that are not captured in the study design. Prospectively collecting patient costs 14 
from symptomatic individuals as part of a TB prevalence survey is an attractive design, but challenging 15 
to implement, due for instance to the geographical spread of small numbers of untracked patients.  16 
 17 
We welcome the suggestion from Timire and colleagues for more evaluations of different social 18 
protection interventions. Findings from ongoing or planned intervention studies in e.g. Vietnam, 19 
Nepal, Uganda and Mozambique, aiming to improve completion of the care pathway through different 20 
modalities of socioeconomic support  will contribute important evidence. Several of these studies are 21 
linked to the Social Protection Action Research & Knowledge Sharing (SPARKS)(3), an international 22 
interdisciplinary research network on social protection, aiming to facilitate networking and knowledge 23 
sharing between academia, public health practitioners, international organizations and civil society. 24 
Government-led schemes such as the Direct Benefit Transfer in India may encourage people to engage 25 
with care, thus addressing another gap that is not tackled by looking at individuals who are lost to 26 
follow-up pre-treatment. This potential needs rigorous evaluation.  27 
 28 
TB patient cost surveys provide important information on how health service delivery and financing 29 
can be changed towards patient-centred care to eliminate TB patient costs, as well as enhancing social 30 
protection measures(2). They are a powerful tool to draw focus towards eliminating the financial 31 
plight and barriers for presumptive and TB patients, through collaboration with relevant stakeholders 32 
within and across the health sector. 33 
 34 
  3 
For example, addressing pre-diagnosis medical costs involves streamlining the TB patient pathway, 35 
expanding access to rapid molecular testing and digital X-rays, intensifying contact investigation and 36 
case finding(4), looking for synergies with programmes on HIV, nutrition, diabetes. 37 
 38 
Ghana, the first country in Africa to conduct a national TB patient cost survey(5), recently developed 39 
a national roadmap to eliminate financial catastrophe for TB patients through a broad multi-sectoral 40 
agenda. The first policy action of this roadmap has led to the decision of the Ghana National Health 41 
Service and National Health Insurance Authority to enrol all TB patients in the National Health 42 
Insurance Scheme free of charge. This should serve as an example and reminder to other countries 43 
and technical partners that ongoing efforts to measure TB-related costs can, and should lead to even 44 
greater concerted efforts to take bold actions towards zero catastrophic costs due to TB, zero TB 45 
suffering and ultimately TB elimination.46 
  4 
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